--- title: "Indivior Pharmaceuticals (INDV) news: class action" url: "https://aibio.space/companies/indivior-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "INDV class action news: Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028. Indivior Pharmaceuticals, Inc." --- INDV Indivior Pharmaceuticals, Inc. NASDAQ · United States # Indivior Pharmaceuticals (INDV) news INDV class action news Legal · 2026-10-29 ## [Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028](https://aibio.space/news/indivior-discloses-suboxone-dental-injury-mdl-about-22-098-plaintiffs/) Indivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc. ## Latest Indivior Pharmaceuticals news 1. 2026-08-03 Debt Financing [Supernus and Indivior plan merger backed by $650 million Citibank loan](https://aibio.space/news/supernus-indivior-plan-merger-backed-650-million-citibank-loan/) Supernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026. 2. 2026-01-26 Mergers [Indivior PLC (now Indivior Pharmaceuticals, Inc.) completes U.S. domestication](https://aibio.space/news/indivior-plc-now-indivior-pharmaceuticals-inc-completes/) The company amended its November 4, 2024 note purchase agreement to reflect that Indivior U.S. now reports the financials. The board carries over, and a 2026 equity plan reserves 17,500,000 shares. 3. 2025-08-26 Distress [Indivior PLC (now Indivior Pharmaceuticals, Inc.) expects $39 to $50 million restructuring charges](https://aibio.space/news/indivior-plc-now-indivior-pharmaceuticals-inc-expects-39-50-million/) Indivior says its Action Agenda initiative brings headcount reductions and real estate consolidations. It expects $27 million to $35 million of the charges to be cash and is exploring strategic alternatives for OPVEE and its non-U.S. business. ## Indivior Pharmaceuticals at a glance - **Ticker**: INDV - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $305.0 million ### Related companies - [Lipella Pharmaceuticals](https://aibio.space/companies/lipella-pharmaceuticals/) OTC: LIPO - [Innoviva](https://aibio.space/companies/innoviva/) NASDAQ: INVA - [Arcutis Biotherapeutics](https://aibio.space/companies/arcutis-biotherapeutics/) NASDAQ: ARQT - [Eikon Therapeutics](https://aibio.space/companies/eikon-therapeutics/) NASDAQ: EIKN - [GT Biopharma](https://aibio.space/companies/gt-biopharma/) NASDAQ: GTBP - [Onconetix](https://aibio.space/companies/onconetix/) NASDAQ: ONCO - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) NASDAQ: AGIO - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) NASDAQ: PBLS ### Also on NASDAQ - [ProQR Therapeutics](https://aibio.space/companies/proqr-therapeutics-n-v/) PRQR - [PACIFIC BIOSCIENCES OF CALIFORNIA, INC.](https://aibio.space/companies/pacific-biosciences-of-california/) PACB - [BioRestorative Therapies](https://aibio.space/companies/biorestorative-therapies/) BRTX - [Lucid Diagnostics](https://aibio.space/companies/lucid-diagnostics/) LUCD - [Anbio Biotechnology](https://aibio.space/companies/anbio-biotechnology/) NNNN - [Dianthus Therapeutics](https://aibio.space/companies/dianthus-therapeutics/) DNTH ## What Indivior Pharmaceuticals does Indivior Pharmaceuticals, Inc. is a market leader in long-acting injectable medications for opioid use disorder (OUD). Its core approved treatments are SUBLOCADE (buprenorphine extended-release monthly injection) and SUBOXONE Film (buprenorphine and naloxone sublingual film). The U.S. accounted for 85% of net revenues in 2025, and in the U.S. the company sells only SUBLOCADE and SUBOXONE Film. SUBUTEX Tablets are distributed primarily in Australia, France and Germany, and SUBOXONE Tablets continue on a transition basis in a limited number of countries. The company's product pipeline includes two new drug candidates for the treatment of OUD. The business was developed as a division of Reckitt Benckiser Group PLC and became standalone after the demerger effective December 23, 2014. On January 23, 2026, Indivior Pharmaceuticals, Inc. became the ultimate parent company of Indivior PLC through a court-approved scheme of arrangement, completing a U.S. domestication. In 2020 the company reached agreements with the Department of Justice and the Federal Trade Commission concerning SUBOXONE marketing and promotional practices. | Product or program | What it is | Stage | |---|---|---| | SUBLOCADE | Monthly buprenorphine extended-release injection for OUD | approved | | SUBOXONE Film | Buprenorphine and naloxone sublingual film for OUD | approved | | SUBUTEX Tablets | Buprenorphine sublingual tablet distributed primarily outside the U.S. | | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm). ## Indivior Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.24 billion](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | [$1.19 billion](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | | Research and development | [$97.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | [$107.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | | Net income (loss) | [$210.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | [$7.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | | Cash from operations | [-$27.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | [$36.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | | Cash and equivalents | [$195.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026068013/) | [$319.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $305.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Indivior Pharmaceuticals Is there a class action against Indivior Pharmaceuticals? Our latest story on this, dated Oct 29, 2026: "Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/indivior-discloses-suboxone-dental-injury-mdl-about-22-098-plaintiffs/). What is the ticker symbol of Indivior Pharmaceuticals? Indivior Pharmaceuticals, Inc. trades under the ticker INDV on NASDAQ. Where is Indivior Pharmaceuticals listed? Indivior Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:E7P; FWB:E7P; GETTEX:E7P; LS:A42086; LSX:A42086; MUN:E7P; TRADEGATE:E7P; XETR:E7P. What is the SEC CIK of Indivior Pharmaceuticals? The SEC Central Index Key (CIK) for Indivior Pharmaceuticals, Inc. is 1625297. Its filings are on SEC EDGAR. How many shares does Indivior Pharmaceuticals have outstanding? 118,013,649 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-03. Which country or territory is Indivior Pharmaceuticals listed under? Our directory records Indivior Pharmaceuticals, Inc. under United States. What does Indivior Pharmaceuticals do? Our directory classifies Indivior Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Indivior Pharmaceuticals? The ISIN recorded for Indivior Pharmaceuticals, Inc. is US45579U1097. Does aibio.space cover Indivior Pharmaceuticals? aibio.space lists Indivior Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Indivior Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Indivior Pharmaceuticals develop? Indivior Pharmaceuticals, Inc. is a market leader in long-acting injectable medications for opioid use disorder (OUD). Its core approved treatments are SUBLOCADE (buprenorphine extended-release monthly injection) and SUBOXONE Film (buprenorphine and naloxone sublingual film). What is SUBLOCADE from Indivior Pharmaceuticals? SUBLOCADE: Monthly buprenorphine extended-release injection for OUD Stage: approved. What is SUBOXONE Film from Indivior Pharmaceuticals? SUBOXONE Film: Buprenorphine and naloxone sublingual film for OUD Stage: approved. What was Indivior Pharmaceuticals's revenue last year? $1.24 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Indivior Pharmaceuticals profitable? Indivior Pharmaceuticals, Inc. reported net income of $210.0 million for the fiscal year ended Dec 31, 2025, and used $27.0 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Indivior Pharmaceuticals Members talk about Indivior Pharmaceuticals (INDV). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Indivior Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-06 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000110465926113883/tm2627060d1_8k.htm) 2. 2026-09-15 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162529726000028/indv-20260909.htm) 3. 2026-08-03 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/d28447dex991.htm) 4. 2026-03-12 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162529726000008/a991ignitelaunchpr.htm) 5. 2026-01-26 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162529726000002/form15.htm) 6. 2025-11-20 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162529725000069/ex991pressreleasedoj.htm) 7. 2025-10-01 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162828025043293/ex99110012025intenttoredom.htm) 8. 2025-08-26 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162529725000059/indv-20250826.htm) 9. 2025-06-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162529725000035/ex991pressreleaseintention.htm) 10. 2025-02-20 Financings Announced a share repurchase program. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1625297/000162529725000003/exhibit991q42024pressrelea.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INDV on TradingView](https://www.tradingview.com/symbols/NASDAQ-INDV/). ## SEC filings and registration - **SEC name**: Indivior Pharmaceuticals, Inc. - **CIK**: 1625297 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: INDV (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD, VA, 23235 - **Phone**: 804-379-1090 - **Shares outstanding**: 118,013,649 as of 2026-07-28 (10-Q filed 2026-08-03) - **Former names**: INDIVIOR PLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926116253/tm2627549d1_8k.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926113883/tm2627060d1_8k.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926108417/tm2623753d7_8k.htm) filed 2026-09-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1625297/000162529726000028/indv-20260909.htm) filed 2026-09-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1625297/000162828026051895/indv-20260630.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1625297/000119312526329618/d166865d8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566d8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/d28447d8k.htm) filed 2026-08-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001625297), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Indivior Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INDV, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Indivior Pharmaceuticals, Inc. - **Ticker**: INDV - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US45579U1097 - **Other listed symbols**: DUS:E7P; FWB:E7P; GETTEX:E7P; LS:A42086; LSX:A42086; MUN:E7P; TRADEGATE:E7P; XETR:E7P - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INDV/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/indivior-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Indivior Pharmaceuticals (INDV) news: class action", 2026-10-31, https://aibio.space/companies/indivior-pharmaceuticals/